Please assess the completion status of the following clinical trial:

Trial Title: Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe UC defined by an overall Mayo score ≥ 5 and an endoscopic sub-score ≥ 2 points and rectal bleeding score ≥ 1 point~* Extension \> 15 cm from the anal margin~* Requiring treatment with biotherapy and meeting the indications for the treatment~* Affiliated with a social security scheme~Exclusion Criteria:~* Crohn's disease or unclassified colitis~* Severe acute colitis~* Requirement for immediate surgical treatment~* Previous treatment with vedolizumab or anti-TNF-α~* Contraindication to the use of vedolizumab or an anti-TNF-α agent~* Contraindication to the use of adalimumab~* Corticosteroid therapy \> 20 mg/day~* Corticosteroid therapy started within the previous two weeks~* Conventional Immunosppressor started within the previous month~* Colonic dysplasia or known cancer~* Likelihood to refuse two rectosigmoidoscopies, performed eighteen weeks apart~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VEDOLIZUMAB (Type: EXPERIMENTAL): 300 mg IV

Based on this trial design, predict the completion outcome and termination type (if applicable).